Table: q1_q4_2020_prescription_drugs_wac_increases , manufacturer_name like E*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000076 Eisai Inc. 03/31/2020 62856070830 LENVIMA (lenvatinib mesylate) 8 mg/day (4 mg x 2) 60 count 01/23/2020 647.00 19021.00 08/26/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Fields related to product acquired within the previous five year period are not applicable.
Rx0000076 Eisai Inc. 03/31/2020 62856071030 LENVIMA (lenvatinib mesylate)10 mg/day (10 mg x 1) 30 count 01/23/2020 647.00 19021.00 08/26/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Fields related to product acquired within the previous five year period are not applicable.
Rx0000076 Eisai Inc. 03/31/2020 62856071430 LENVIMA (lenvatinib mesylate)14 mg/day (10 mg x 1 and 4 mg x 1) 60 count 01/23/2020 647.00 19021.00 08/26/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Fields related to product acquired within the previous five year period are not applicable.
Rx0000114 Eli Lilly and Company 03/31/2020 00002144511 TALTZ™ 80 mg/mL disposable autoinjector (1 pack) 01/31/2020 322.00 5690.00 12/06/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering TALTZ™ and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of TALTZ™. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. This product was not acquired within the last 5 years, therefore columns 14-21 are intentionally left blank.
Rx0000114 Eli Lilly and Company 03/31/2020 00002144527 TALTZ™ 80 mg/mL disposable autoinjector (2 pack) 01/31/2020 644.00 11380.00 12/06/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering TALTZ™ and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of TALTZ™. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. This product was not acquired within the last 5 years, therefore columns 14-21 are intentionally left blank.
Rx0000114 Eli Lilly and Company 03/31/2020 00002144509 TALTZ™ 80 mg/mL disposable autoinjector (3 pack) 01/31/2020 966.00 17070.00 12/06/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering TALTZ™ and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of TALTZ™. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. This product was not acquired within the last 5 years, therefore columns 14-21 are intentionally left blank.
Rx0000114 Eli Lilly and Company 03/31/2020 00002772411 TALTZ™ 80 mg/mL disposable prefilled syringe (1 per carton) 01/31/2020 322.00 5690.00 12/06/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering TALTZ™ and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of TALTZ™. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. This product was not acquired within the last 5 years, therefore columns 14-21 are intentionally left blank.
Rx0000114 Eli Lilly and Company 03/31/2020 00002143380 TRULICITY™ 0.75 mg/0.5 mL carton of 4 single-dose pens 01/31/2020 37.90 797.30 12/27/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering TRULICITY™ and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of TRULICITY™. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. This product was not acquired within the last 5 years, therefore columns 14-21 are intentionally left blank.
Rx0000114 Eli Lilly and Company 03/31/2020 00002143480 TRULICITY™ 1.5 mg /0.5mL carton of 4 single-dose pens 01/31/2020 37.90 797.30 12/27/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering TRULICITY™ and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of TRULICITY™. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. This product was not acquired within the last 5 years, therefore columns 14-21 are intentionally left blank.
Rx0000079 EMD Serono, Inc. 03/31/2020 44087907001 Gonal-f Multi-Dose 1050IU (1) 01/10/2020 192.08 2753.66 08/23/2019 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 03/31/2020 44087903001 Gonal-f Multi-Dose 450IU (1) 01/10/2020 82.32 1180.14 08/23/2019 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 03/31/2020 44087900501 Gonal-f RFF* 75IU (1) 01/10/2020 13.72 196.69 04/02/2024 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 03/31/2020 44087900506 Gonal-f RFF* 75IU (10) 01/10/2020 137.20 1966.90 04/02/2024 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 03/31/2020 44087111501 Gonal-f RFF* Redi-ject™ 300IU (1) 01/10/2020 54.88 786.76 04/02/2024 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 03/31/2020 44087111601 Gonal-f RFF* Redi-ject™ 450IU (1) 01/10/2020 82.32 1180.14 04/02/2024 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 03/31/2020 44087111701 Gonal-f RFF* Redi-ject™ 900IU (1) 01/10/2020 164.64 2360.28 04/02/2024 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 03/31/2020 44087115001 Ovidrel Subcutaneous Injectable 250 MCG/0.5ML (1) 01/10/2020 12.38 177.49 03/16/2021 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000091 Endo Pharmaceuticals Inc. 06/30/2020 67979051143 Aveed, 750 mg/3mL (250mg/1mL) solution, single use vial 04/01/2020 59.61 1288.78 03/14/2027 Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 7/20/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 12/31/2020 67979051143 Aveed, 750 mg/3mL (250mg/1mL) solution, single use vial 10/01/2020 62.51 1351.29 05/08/2027 Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration's Orange Book, as of 1/22/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 52244092010 DILATRATE®, Isosorbide Dinitrate Cap ER 40 MG, 100 01/06/2020 41.97 465.90 None Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None 01/29/2015 Auxilium Pharmaceuticals None None 1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. 302.93 275.64 2012 192.75 None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 52244001002 Edex®, Alprostadil For Inj Kit 10 MCG, 2 01/06/2020 7.65 135.07 None Innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None 01/29/2015 Auxilium Pharmaceuticals None None 1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. 99.06 90.14 2012 78.00 None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 52244001006 Edex®, Alprostadil For Inj Kit 10 MCG, 6 01/06/2020 22.94 405.25 None Innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None 01/29/2015 Auxilium Pharmaceuticals None None 1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. 297.19 270.42 2012 234.00 None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 52244002002 Edex®, Alprostadil For Inj Kit 20 MCG, 2 01/06/2020 9.88 174.49 None Innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None 01/29/2015 Auxilium Pharmaceuticals None None 1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. 127.96 116.43 2012 100.75 None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 52244002006 Edex®, Alprostadil For Inj Kit 20 MCG, 6 01/06/2020 29.63 523.44 None Innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None 01/29/2015 Auxilium Pharmaceuticals None None 1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. 383.87 349.29 2012 302.25 None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 52244004002 Edex®, Alprostadil For Inj Kit 40 MCG, 2 01/06/2020 13.49 238.28 None Innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None 01/29/2015 Auxilium Pharmaceuticals None None 1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. 174.75 159.01 2012 137.60 None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 52244004006 Edex®, Alprostadil For Inj Kit 40 MCG, 6 01/06/2020 40.46 714.80 None Innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None 01/29/2015 Auxilium Pharmaceuticals None None 1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. 524.21 476.99 2012 412.75 None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 63481002509 FROVA®, Frovatriptan Succinate Tab 2.5 MG (Base Equivalent), 9 01/06/2020 79.24 879.63 None Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 63481068706 LIDODERM®, Lidocaine Patch 5%, 30 01/06/2020 53.97 599.08 None Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 49884027082 NASCOBAL®, Cyanocobalamin Nasal Spray 500 MCG/0.1ML, 1 01/06/2020 28.70 614.48 08/01/2024 Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None 09/28/2015 Par Pharmaceutical None None 1) Endo acquired Par Pharmaceutical on 9/25/15. As a part of Endo’s acquisition of Par Pharmaceutical, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Par Pharmaceutical to the individual assets or products acquired from Par Pharmaceutical. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. 396.88 361.13 2014 361.13 None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 63481062970 PERCOCET®, Oxycodone w/ Acetaminophen Tab 10-325 MG, 100 01/06/2020 231.86 2573.92 None Non-innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 63481062770 PERCOCET®, Oxycodone w/ Acetaminophen Tab 2.5-325 MG, 100 01/06/2020 117.27 1301.84 None Non-innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 63481062370 PERCOCET®, Oxycodone w/ Acetaminophen Tab 5-325 MG, 100 01/06/2020 164.13 1822.02 None Non-innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 63481062385 PERCOCET®, Oxycodone w/ Acetaminophen Tab 5-325 MG, 500 01/06/2020 800.01 8880.92 None Non-innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 63481062870 PERCOCET®, Oxycodone w/ Acetaminophen Tab 7.5-325 MG, 100 01/06/2020 177.32 1968.45 None Non-innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 52244044910 ROBAXIN®, Methocarbamol Tab 750 MG, 100 01/06/2020 26.64 295.72 None Innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None 01/29/2015 Auxilium Pharmaceuticals None None 1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. 202.71 202.71 2011 233.00 None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 52244040410 SEMPREX®-D, Acrivastine & Pseudoephedrine Cap 8-60 MG, 100 01/06/2020 54.01 599.61 None Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None 01/29/2015 Auxilium Pharmaceuticals None None 1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. 339.70 308.82 2012 212.50 None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091 Endo Pharmaceuticals Inc. 06/30/2020 67979000201 Supprelin LA, 50 mg implant, ea 04/01/2020 1811.31 39157.87 06/16/2026 Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 7/20/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 12/31/2020 67979000201 Supprelin LA, 50 mg implant, ea 10/01/2020 1899.16 41057.03 06/16/2026 Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration's Orange Book, as of 1/22/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 52244010010 THEO-24®, Theophylline Cap ER 24HR 100 MG, 100 01/06/2020 21.74 241.34 None Non-innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None 01/29/2015 Auxilium Pharmaceuticals None None 1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. 136.73 0.00 2014 136.73 None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 52244020010 THEO-24®, Theophylline Cap ER 24HR 200 MG, 100 01/06/2020 32.31 358.68 None Non-innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None 01/29/2015 Auxilium Pharmaceuticals None None 1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. 203.21 0.00 2014 203.21 None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 52244030010 THEO-24®, Theophylline Cap ER 24HR 300 MG, 100 01/06/2020 39.71 440.85 None Non-innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None 01/29/2015 Auxilium Pharmaceuticals None None 1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. 249.75 0.00 2014 249.75 None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2020 52244040010 THEO-24®, Theophylline Cap ER 24HR 400 MG, 100 01/06/2020 55.88 620.33 None Non-innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug None 01/29/2015 Auxilium Pharmaceuticals None None 1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. 351.43 0.00 2014 351.43 None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091 Endo Pharmaceuticals Inc. 06/30/2020 67979000101 Valstar, 40 mg/1ml solution, 4x5mL 04/01/2020 294.84 6373.98 None Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 7/20/2020, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 12/31/2020 67979000101 Valstar, 40 mg/1ml solution, 4x5mL 10/01/2020 309.14 6683.12 None Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 1/22/2021, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 06/30/2020 67979050001 Vantas, 50 mg implant, ea 04/01/2020 215.02 4648.41 None Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 7/20/2020, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 12/31/2020 67979050001 Vantas, 50 mg implant, ea 10/01/2020 225.45 4873.86 None Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 1/22/2021, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 06/30/2020 66887000301 Xiaflex, 0.9mg powder for solution, single use vial 04/01/2020 181.99 4848.34 None Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The federal Food and Drug Administration’s Purple Book does not require the listing of patents or their expiration dates for any product, including Xiaflex. The patent expiration date for any patent potentially associated with Xiaflex would also depend on pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten such an expiration date. As a result, Endo has left the patent expiration date field for this product blank. (3) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation.
Rx0000091 Endo Pharmaceuticals Inc. 12/31/2020 66887000301 Xiaflex, 0.9mg powder for solution, single use vial 10/01/2020 189.09 5037.43 None Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The federal Food and Drug Administration's Purple Book does not require the listing of patents or their expiration dates for any product, including Xiaflex. The patent expiration date for any patent potentially associated with Xiaflex would also depend on pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten such an expiration date. As a result, Endo has left the patent expiration date field for this product blank. (3) For 'Year Introduced', Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation.
Rx0000094 Epic Pharma 06/30/2020 42806005030 Meperidine Hcl 50mg30 Tab Epic 06/26/2020 234.90 1017.90 None Non-innovator Multiple Source Drug None 1 None 1 None 1 07/13/2010 Mikah Pharma LLC None 1 None 783.00 783.00 2003 783.00 None Epic Pharma lauched this new size-30 count sku in 12/31/2019.Prior companies didn’t have WAC data for this new sku.
Rx0000094 Epic Pharma 06/30/2020 42806033701 Molindone 10mg 100 Tab 06/26/2020 223.50 968.50 None Non-innovator Multiple Source Drug None 1 None 1 None 1 05/26/2017 CorePharma,LLC None 1 None 183.46 183.46 2015 183.46 None None
Rx0000094 Epic Pharma 06/30/2020 42806033801 Molindone 25mg 100 Tab 06/26/2020 249.00 1079.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 05/26/2017 CorePharma,LLC None 1 None 215.48 215.48 2015 215.48 None None
Rx0000094 Epic Pharma 06/30/2020 42806033601 Molindone 5mg 100 Tab 06/26/2020 186.00 806.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 05/26/2017 CorePharma,LLC None 1 None 127.60 127.60 2015 127.60 None None
Rx0000094 Epic Pharma 06/30/2020 42806050109 Nicardipine Hcl 20mg90 Cap Epic 06/26/2020 318.74 1115.59 None Non-innovator Multiple Source Drug None 1 None 1 None 1 06/24/2010 Amneal Pharmaceuticals None 1 None 9.65 9.65 2006 9.65 None the original manufacture Genpharm/ lipha introduced the products on market in 2006, but there is no WAC. Amneal bought this product and then they introduced to maket with WAC $9.65 in 2008.
Rx0000094 Epic Pharma 06/30/2020 42806050209 Nicardipine Hcl 30mg90 Cap Epic 06/26/2020 456.50 1597.76 None Non-innovator Multiple Source Drug None 1 None 1 None 1 06/24/2010 Amneal Pharmaceuticals None 1 None 14.90 14.90 2006 14.90 None the original manufacture Genpharm/ lipha introduced the products on market in 2006, but there is no WAC. Amneal bought this product and then they introduced to maket with WAC $14.9 in 2008.
Rx0000104 EUSA Pharma (US) LLC 12/31/2020 57894042001 SYLVANT, 100mg, intravenous powder for solution 10/01/2020 101.79 1173.26 08/01/2027 Single Source Drug None 1 None 1 None 1 12/22/2018 Janssen Biotech 115000000 None Acquisition price is for both NDCs 910.24 883.73 2014 833.00 None None
Rx0000104 EUSA Pharma (US) LLC 12/31/2020 57894042101 SYLVANT, 400mg, intravenous powder for solution 10/01/2020 407.16 4693.03 08/01/2027 Single Source Drug None 1 None 1 None 1 12/22/2018 Janssen Biotech 115000000 None Acquisition price is for both NDCs 3640.96 3534.92 2014 3332.00 None None
Rx0000010 Exelixis, Inc. 03/31/2020 42388002426 CABOMETYX 20MG 30 TAB BTL EACH 01/01/2020 959.59 20151.54 07/09/2033 Single Source Drug None 1 Exelixis? Mission: Exelixis strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. That mission, however, entails tremendous risk of failure and research and development costs that total in the billions of dollars. At the present time, CABOMETYX? and COMETRIQ?, both derived from the same molecule, cabozantinib, are the only products that Exelixis sells and comprise the vast majority of Exelixis? revenue. Exelixis is committed to spending the largest portion of this revenue on drug discovery research and clinical development, and to pricing CABOMETYX consistent with its value when compared to competitive products approved for similar conditions. Drug Discovery Factors: Having recently constructed new laboratory facilities, Exelixis re-launched its drug discovery activities in 2018 and is working to discover the next generation of cancer therapies. Exelixis considered the investments necessary to undertake and support these drug discovery efforts when it contemplated changes to CABOMETYX?s wholesale acquisition cost. Cabozantinib Development Factors: Since the initial commercial launch of cabozantinib, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in an extremely broad and diverse collection of additional cancers. Alone and in combination with other therapies, it is currently being studied in over 100 clinical trials for over 20 different forms of cancer. Exelixis considered the cost of this clinical development program, and the need to expand it to reach cabozantinib?s full potential for treating the largest number of cancer patients, when it contemplated changes to the wholesale acquisition cost of CABOMETYX. CABOMETYX Value Factors: CABOMETYX has been approved by the FDA to treat patients with liver and kidney cancer and has shown impressive efficacy relative to its competitors in treating patients with these life-threatening diseases. It is the only drug of its kind to improve overall survival in a statistically significant manner in both kidney and liver cancer. When Exelixis contemplated a change to the wholesale acquisition cost for CABOMETYX, Exelixis considered the clinical value proposition of CABOMETYX relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors. CABOMETYX Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To secure that the supply of CABOMETYX for our customers, and ultimately, patients is safe and interrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of CABOMETYX, Exelixis considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising manufacturing costs. None It is Exelixis' stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer. To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities. In pre-clinical and clinical testing, cabozantinib has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving cabozantinib by exploring the medicine's full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of CABOMETYX? when market conditions permit such an increase. None None None None None None None None None None None Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 10/30/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date
Rx0000010 Exelixis, Inc. 03/31/2020 42388002526 CABOMETYX 40MG 30 TAB BTL EACH 01/01/2020 959.59 20151.54 07/09/2033 Single Source Drug None 1 Exelixis? Mission: Exelixis strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. That mission, however, entails tremendous risk of failure and research and development costs that total in the billions of dollars. At the present time, CABOMETYX? and COMETRIQ?, both derived from the same molecule, cabozantinib, are the only products that Exelixis sells and comprise the vast majority of Exelixis? revenue. Exelixis is committed to spending the largest portion of this revenue on drug discovery research and clinical development, and to pricing CABOMETYX consistent with its value when compared to competitive products approved for similar conditions. Drug Discovery Factors: Having recently constructed new laboratory facilities, Exelixis re-launched its drug discovery activities in 2018 and is working to discover the next generation of cancer therapies. Exelixis considered the investments necessary to undertake and support these drug discovery efforts when it contemplated changes to CABOMETYX?s wholesale acquisition cost. Cabozantinib Development Factors: Since the initial commercial launch of cabozantinib, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in an extremely broad and diverse collection of additional cancers. Alone and in combination with other therapies, it is currently being studied in over 100 clinical trials for over 20 different forms of cancer. Exelixis considered the cost of this clinical development program, and the need to expand it to reach cabozantinib?s full potential for treating the largest number of cancer patients, when it contemplated changes to the wholesale acquisition cost of CABOMETYX. CABOMETYX Value Factors: CABOMETYX has been approved by the FDA to treat patients with liver and kidney cancer and has shown impressive efficacy relative to its competitors in treating patients with these life-threatening diseases. It is the only drug of its kind to improve overall survival in a statistically significant manner in both kidney and liver cancer. When Exelixis contemplated a change to the wholesale acquisition cost for CABOMETYX, Exelixis considered the clinical value proposition of CABOMETYX relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors. CABOMETYX Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To secure that the supply of CABOMETYX for our customers, and ultimately, patients is safe and interrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of CABOMETYX, Exelixis considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising manufacturing costs. None It is Exelixis' stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer. To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities. In pre-clinical and clinical testing, cabozantinib has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving cabozantinib by exploring the medicine's full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of CABOMETYX? when market conditions permit such an increase. None None None None None None None None None None None Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 10/30/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date
Rx0000010 Exelixis, Inc. 03/31/2020 42388002326 CABOMETYX 60MG 30 TAB BTL EACH 01/01/2020 959.59 20151.54 07/09/2033 Single Source Drug None 1 Exelixis? Mission: Exelixis strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. That mission, however, entails tremendous risk of failure and research and development costs that total in the billions of dollars. At the present time, CABOMETYX? and COMETRIQ?, both derived from the same molecule, cabozantinib, are the only products that Exelixis sells and comprise the vast majority of Exelixis? revenue. Exelixis is committed to spending the largest portion of this revenue on drug discovery research and clinical development, and to pricing CABOMETYX consistent with its value when compared to competitive products approved for similar conditions. Drug Discovery Factors: Having recently constructed new laboratory facilities, Exelixis re-launched its drug discovery activities in 2018 and is working to discover the next generation of cancer therapies. Exelixis considered the investments necessary to undertake and support these drug discovery efforts when it contemplated changes to CABOMETYX?s wholesale acquisition cost. Cabozantinib Development Factors: Since the initial commercial launch of cabozantinib, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in an extremely broad and diverse collection of additional cancers. Alone and in combination with other therapies, it is currently being studied in over 100 clinical trials for over 20 different forms of cancer. Exelixis considered the cost of this clinical development program, and the need to expand it to reach cabozantinib?s full potential for treating the largest number of cancer patients, when it contemplated changes to the wholesale acquisition cost of CABOMETYX. CABOMETYX Value Factors: CABOMETYX has been approved by the FDA to treat patients with liver and kidney cancer and has shown impressive efficacy relative to its competitors in treating patients with these life-threatening diseases. It is the only drug of its kind to improve overall survival in a statistically significant manner in both kidney and liver cancer. When Exelixis contemplated a change to the wholesale acquisition cost for CABOMETYX, Exelixis considered the clinical value proposition of CABOMETYX relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors. CABOMETYX Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To secure that the supply of CABOMETYX for our customers, and ultimately, patients is safe and interrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of CABOMETYX, Exelixis considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising manufacturing costs. None It is Exelixis' stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer. To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities. In pre-clinical and clinical testing, cabozantinib has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving cabozantinib by exploring the medicine's full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of CABOMETYX? when market conditions permit such an increase. None None None None None None None None None None None Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 10/30/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date
Rx0000010 Exelixis, Inc. 03/31/2020 42388001214 COMETRIQ 100 MG DAILY-DOSE PACK, 56 ct (4 X 14 ct Blister Cards Per Package) 01/01/2020 857.11 17999.31 02/10/2032 Single Source Drug None 1 Exelixis? Mission: Exelixis strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. That mission, however, entails tremendous risk of failure and research and development costs that total in the billions of dollars. At the present time, CABOMETYX? and COMETRIQ?, both derived from the same molecule, cabozantinib, are the only products that Exelixis sells and comprise the vast majority of Exelixis? revenue. Exelixis is committed to spending the largest portion of this revenue on drug discovery research and clinical development, and to pricing COMETRIQ consistent with its value when compared to competitive products approved for similar conditions. Drug Discovery Factors: Having recently constructed new laboratory facilities, Exelixis re-launched its drug discovery activities in 2018 and is working to discover the next generation of cancer therapies. Exelixis considered the investments necessary to undertake and support these drug discovery efforts when it contemplated changes to COMETRIQ?s wholesale acquisition cost. Cabozantinib Development Factors: Since the initial commercial launch of cabozantinib, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in an extremely broad and diverse collection of additional cancers. Alone and in combination with other therapies, it is currently being studied in over 100 clinical trials for over 20 different forms of cancer. Exelixis considered the cost of this clinical development program, and the need to expand it to reach cabozantinib?s full potential for treating the largest number of cancer patients, when it contemplated changes to the wholesale acquisition cost of COMETRIQ. COMETRIQ Value Factors: COMETRIQ has been approved by the FDA to treat patients with medullary thyroid cancer and has shown impressive efficacy relative to its competitors in treating patients with this life-threatening disease. When Exelixis contemplated a change to the wholesale acquisition cost for COMETRIQ, Exelixis considered the clinical value proposition of COMETRIQ relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors. COMETRIQ Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To secure that the supply of COMETRIQ for our customers, and ultimately, patients is safe and interrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of COMETRIQ, Exelixis considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising manufacturing costs. None It is Exelixis? stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer.? To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities.? In pre-clinical and clinical testing, cabozantinib has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving cabozantinib by exploring the medicine?s full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of COMETRIQ? when market conditions permit such an increase. None None None None None None None None None None None Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 10/30/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date
Rx0000010 Exelixis, Inc. 03/31/2020 42388001114 COMETRIQ 140 MG DAILY-DOSE PACK, 112 ct (4 X 28 ct Blister Cards Per Package) 01/01/2020 857.11 17999.31 02/10/2032 Single Source Drug None 1 Exelixis? Mission: Exelixis strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. That mission, however, entails tremendous risk of failure and research and development costs that total in the billions of dollars. At the present time, CABOMETYX? and COMETRIQ?, both derived from the same molecule, cabozantinib, are the only products that Exelixis sells and comprise the vast majority of Exelixis? revenue. Exelixis is committed to spending the largest portion of this revenue on drug discovery research and clinical development, and to pricing COMETRIQ consistent with its value when compared to competitive products approved for similar conditions. Drug Discovery Factors: Having recently constructed new laboratory facilities, Exelixis re-launched its drug discovery activities in 2018 and is working to discover the next generation of cancer therapies. Exelixis considered the investments necessary to undertake and support these drug discovery efforts when it contemplated changes to COMETRIQ?s wholesale acquisition cost. Cabozantinib Development Factors: Since the initial commercial launch of cabozantinib, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in an extremely broad and diverse collection of additional cancers. Alone and in combination with other therapies, it is currently being studied in over 100 clinical trials for over 20 different forms of cancer. Exelixis considered the cost of this clinical development program, and the need to expand it to reach cabozantinib?s full potential for treating the largest number of cancer patients, when it contemplated changes to the wholesale acquisition cost of COMETRIQ. COMETRIQ Value Factors: COMETRIQ has been approved by the FDA to treat patients with medullary thyroid cancer and has shown impressive efficacy relative to its competitors in treating patients with this life-threatening disease. When Exelixis contemplated a change to the wholesale acquisition cost for COMETRIQ, Exelixis considered the clinical value proposition of COMETRIQ relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors. COMETRIQ Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To secure that the supply of COMETRIQ for our customers, and ultimately, patients is safe and interrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of COMETRIQ, Exelixis considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising manufacturing costs. None It is Exelixis? stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer.? To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities.? In pre-clinical and clinical testing, cabozantinib has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving cabozantinib by exploring the medicine?s full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of COMETRIQ? when market conditions permit such an increase. None None None None None None None None None None None Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 10/30/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date
Rx0000010 Exelixis, Inc. 03/31/2020 42388001314 COMETRIQ 60 MG DAILY-DOSE PACK, 84 ct (4 X 21 ct Blister Cards Per Package) 01/01/2020 857.11 17999.31 02/10/2032 Single Source Drug None 1 Exelixis? Mission: Exelixis strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. That mission, however, entails tremendous risk of failure and research and development costs that total in the billions of dollars. At the present time, CABOMETYX? and COMETRIQ?, both derived from the same molecule, cabozantinib, are the only products that Exelixis sells and comprise the vast majority of Exelixis? revenue. Exelixis is committed to spending the largest portion of this revenue on drug discovery research and clinical development, and to pricing COMETRIQ consistent with its value when compared to competitive products approved for similar conditions. Drug Discovery Factors: Having recently constructed new laboratory facilities, Exelixis re-launched its drug discovery activities in 2018 and is working to discover the next generation of cancer therapies. Exelixis considered the investments necessary to undertake and support these drug discovery efforts when it contemplated changes to COMETRIQ?s wholesale acquisition cost. Cabozantinib Development Factors: Since the initial commercial launch of cabozantinib, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in an extremely broad and diverse collection of additional cancers. Alone and in combination with other therapies, it is currently being studied in over 100 clinical trials for over 20 different forms of cancer. Exelixis considered the cost of this clinical development program, and the need to expand it to reach cabozantinib?s full potential for treating the largest number of cancer patients, when it contemplated changes to the wholesale acquisition cost of COMETRIQ. COMETRIQ Value Factors: COMETRIQ has been approved by the FDA to treat patients with medullary thyroid cancer and has shown impressive efficacy relative to its competitors in treating patients with this life-threatening disease. When Exelixis contemplated a change to the wholesale acquisition cost for COMETRIQ, Exelixis considered the clinical value proposition of COMETRIQ relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors. COMETRIQ Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To secure that the supply of COMETRIQ for our customers, and ultimately, patients is safe and interrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of COMETRIQ, Exelixis considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising manufacturing costs. None It is Exelixis? stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer.? To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities.? In pre-clinical and clinical testing, cabozantinib has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving cabozantinib by exploring the medicine?s full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of COMETRIQ? when market conditions permit such an increase. None None None None None None None None None None None Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 10/30/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date
Rx0000205 Eyevance Pharmaceuticals LLC 12/31/2020 71776010005 Flarex (fluorometholone acetate), ophthalmic suspension, 0.1%, 5mL 10/24/2020 29.11 119.07 None Single Source Drug None 1 None 1 None 1 10/23/2018 Novartis AG None 1 None 70.01 70.01 1986 7.48 None (1) We do not have the actual price when the product was introduced as it was purchased. For this entry, we used the baseline Average Manufacturers Price (AMP) that was established for the product when the Medicaid Pricing Program began. This is the best estimation available for an introductory market price. (2) The NDC# prior to the Eyevance NDC# was 00065-0096-05. In the 5 Year WAC history field we used the current Eyevance NDC# (71776-0100-05) although the WAC increases prior to 2020 were reflective of the old 00065-0096-05 NDC#.